Xencor (XNCR) Stock Forecast & Price Target

Xencor is viewed favorably because XmAb819 delivered stronger-than-expected efficacy in advanced ccRCC, with a 45.5% confirmed ORR, an 82% 6-month PFS estimate, and manageable safety at the proposed 400 µg/kg dose. The company also has a clearer registrational path, including a potential accelerated approval discussion with regulators in 1H27, a planned randomized study targeted to begin by YE27, and optionality to move earlier in ccRCC and into additional tumors. Financially, 3Q26 EPS of $0.50 beat expectations, helped by a $25 million Astellas milestone and about $66.9 million from selling roughly 2.1 million Zenas shares, while its broader partnered and autoimmune pipeline adds near-term value support.

Xencor is viewed negatively because its core value depends on early-stage oncology and autoimmune programs that carry high clinical uncertainty, with limited de-risking data to date and no sizable, definitive efficacy or safety readouts yet. Competitive pressure in these crowded spaces could force higher investor expectations even if trials succeed, while regulatory or clinical delays could further weaken confidence in the pipeline. Financially, the company may need additional capital before commercialization of its wholly owned portfolio, and revenue from partnerships, milestones, and royalties remains dependent on continued development and clinical success.